PL2086576T3 - Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne - Google Patents

Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne

Info

Publication number
PL2086576T3
PL2086576T3 PL07863555T PL07863555T PL2086576T3 PL 2086576 T3 PL2086576 T3 PL 2086576T3 PL 07863555 T PL07863555 T PL 07863555T PL 07863555 T PL07863555 T PL 07863555T PL 2086576 T3 PL2086576 T3 PL 2086576T3
Authority
PL
Poland
Prior art keywords
proteins
nucleic acid
those
acid molecules
vectors encoding
Prior art date
Application number
PL07863555T
Other languages
English (en)
Inventor
Eric M Vaughn
Paulino Carlos Gonzalez-Hemandez
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of PL2086576T3 publication Critical patent/PL2086576T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07863555T 2006-10-27 2007-10-26 Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne PL2086576T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP07863555.4A EP2086576B8 (en) 2006-10-27 2007-10-26 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Publications (1)

Publication Number Publication Date
PL2086576T3 true PL2086576T3 (pl) 2012-12-31

Family

ID=39325469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07863555T PL2086576T3 (pl) 2006-10-27 2007-10-26 Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne

Country Status (18)

Country Link
US (3) US8202967B2 (pl)
EP (1) EP2086576B8 (pl)
JP (2) JP5442442B2 (pl)
KR (2) KR101520307B1 (pl)
AU (1) AU2007308869B2 (pl)
BR (1) BRPI0718183B8 (pl)
CA (1) CA2664914C (pl)
CO (1) CO6210831A2 (pl)
DK (1) DK2086576T3 (pl)
ES (1) ES2391123T3 (pl)
MX (1) MX2009004243A (pl)
MY (1) MY150226A (pl)
PL (1) PL2086576T3 (pl)
PT (1) PT2086576E (pl)
RU (1) RU2479589C2 (pl)
SG (1) SG176419A1 (pl)
SI (1) SI2086576T1 (pl)
WO (1) WO2008052173A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626866A1 (en) * 2005-10-28 2007-05-10 Boehringer Ingelheim Vetmedica, Inc. Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
CN102271704A (zh) 2008-11-28 2011-12-07 梅里亚有限公司 重组禽流感疫苗及其用途
SG183514A1 (en) * 2010-03-11 2012-10-30 Immune Design Corp Vaccines for pandemic influenza
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
MX360137B (es) * 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
JP7337921B2 (ja) * 2018-11-06 2023-09-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 鳥インフルエンザウイルスｈ５亜型に対する免疫原性組成物
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用
WO2026013162A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Herpes virus of turkey vector based h5ha vaccine for the treatment and prevention of avian influenza infections in turkeys
WO2026013161A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Prime and boost vaccination for the treatment and prevention of avian influenza infections in avians

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
HK1004060A1 (en) 1990-04-24 1998-11-13 Flustat Pty Ltd Oral vaccine comprising antigen surface-associated with red blood cells
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
ATE298370T1 (de) 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
US5928913A (en) 1995-03-23 1999-07-27 Efstathiou; Stacey Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US20020095197A1 (en) 2000-07-11 2002-07-18 Lardo Albert C. Application of photochemotherapy for the treatment of cardiac arrhythmias
JPWO2002062381A1 (ja) * 2001-02-05 2004-06-03 久光製薬株式会社 バキュロウイルスベクターワクチン
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
JP2005539039A (ja) 2002-08-27 2005-12-22 ダウ アグロサイエンシィズ エルエルシー 鳥類及び家禽類におけるアジュバントとしてのエシェリシア・コリ熱不安定性毒素の使用
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2005004222A1 (en) 2003-07-04 2005-01-13 Koninklijke Philips Electronics N.V. Precursor solution, method of preparation thereof and use thereof
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
EP1766059B1 (en) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
EP1877088B1 (en) * 2005-04-11 2014-12-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine against pandemic strains of influenza viruses
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
TWI488968B (zh) 2005-10-18 2015-06-21 Novavax Inc 功能性流行性感冒類病毒顆粒（ＶＬＰｓ）
CA2626866A1 (en) * 2005-10-28 2007-05-10 Boehringer Ingelheim Vetmedica, Inc. Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.

Also Published As

Publication number Publication date
US8592558B2 (en) 2013-11-26
AU2007308869B2 (en) 2013-10-24
WO2008052173A8 (en) 2011-02-03
EP2086576A2 (en) 2009-08-12
RU2009119597A (ru) 2010-12-10
SI2086576T1 (sl) 2012-11-30
ES2391123T3 (es) 2012-11-21
BRPI0718183B8 (pt) 2022-05-24
EP2086576A4 (en) 2011-01-19
SG176419A1 (en) 2011-12-29
KR20150041200A (ko) 2015-04-15
DK2086576T3 (da) 2012-10-15
EP2086576B1 (en) 2012-07-18
MY150226A (en) 2013-12-31
JP5442442B2 (ja) 2014-03-12
WO2008052173A3 (en) 2008-11-13
US20140050755A1 (en) 2014-02-20
US9375469B2 (en) 2016-06-28
WO2008052173A9 (en) 2012-03-22
US20120231027A1 (en) 2012-09-13
JP2010508030A (ja) 2010-03-18
BRPI0718183B1 (pt) 2020-03-17
BRPI0718183A2 (pt) 2013-11-05
US8202967B2 (en) 2012-06-19
KR101520307B1 (ko) 2015-05-29
RU2479589C2 (ru) 2013-04-20
CA2664914A1 (en) 2008-05-02
AU2007308869A1 (en) 2008-05-02
WO2008052173A2 (en) 2008-05-02
PT2086576E (pt) 2012-10-11
KR20090078362A (ko) 2009-07-17
JP2014012008A (ja) 2014-01-23
MX2009004243A (es) 2009-05-14
CO6210831A2 (es) 2010-10-20
US20080193471A1 (en) 2008-08-14
EP2086576B8 (en) 2015-02-18
CA2664914C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
PL2086576T3 (pl) Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne
IL213039A (en) Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
IL205036A (en) Polypeptides, pharmaceutical preparations containing their uses and a nucleic acid encoding them
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
ZA200900494B (en) DNA Molecules and methods
ZA200902409B (en) Lingo binding molecules and pharmaceutical use thereof
PL1999141T3 (pl) Nowe geny kodujące białka owadobójcze
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
EP2126072A4 (en) MATERIALS AND METHOD FOR THE INDIVIDUAL MOLECULE SEQUENCING OF NUCLEIC ACIDS
PL1751278T3 (pl) Cząsteczki kwasu nukleinowego Nicotiana i ich zastosowanie
IL193700A0 (en) Medicaments and proteins
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
GB0602992D0 (en) Methods, genes and proteins
IL193699A0 (en) Proteins, nucleic acids and medicaments
ZA201002799B (en) Improved nogo-a binding molecules and pharmaceutical use thereof
GB2447591B (en) Isolating both free and protein associated DNA
EP2235200A4 (en) NUCLEIC ACID AND AFFINITY TAG PROTEIN COMPOSITIONS, AND METHODS FOR THEIR USE
ZA200902023B (en) Novel H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
ZA201200046B (en) Therapeutic peptides, polypeptides and nucleic acid sequences
TWI365882B (en) Shigella ipab803 protein, producing method and coding nucleic acid thereof
GB0724832D0 (en) Proteins and nucleic acids
PL382703A1 (pl) Cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka
ZA201101924B (en) Novel dna ligase and nucleic acid molecules encoding the same